{"database": "openregs", "table": "dockets", "rows": [["FDA-2026-N-0707", "FDA", "GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg base and EQ 25 mg base", "Nonrulemaking", "2026-04-10T13:40:29Z", "0b000064b917b332"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2026-N-0707"], "units": {}, "query_ms": 0.42929709888994694, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}